C4 Therapeutics, Inc. (CCCC)

Every figure this model derived for CCCC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 523,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 342,712,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 262,902,000 AssetsCurrent 2026-06-30
current liabilities 48,247,000 LiabilitiesCurrent 2026-06-30
equity 247,265,000 StockholdersEquity 2026-06-30
ocf -84,870,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 35,039,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 14,307,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CCCC on one particular measure came for.

RatioValue
cash operating margin-273.98
current ratio12.18
current ratio reported5.45
deferred revenue growth17.86
dilution pct19.51
fcf margin-243.71
growth cv23.86
operating margin-318.97
owner earnings margin-284.54
revenue growth2.33
revenue growth per share-14.37
rule of 40-316.64
sbc pct revenue40.83

What to be careful about

What this model itself distrusts about CCCC's figures. Written by the derivation as it ran, not added afterwards.